Basic information Safety Supplier Related

ml390

Basic information Safety Supplier Related

ml390 Basic information

Product Name:
ml390
Synonyms:
  • ml390
  • Benzamide, N-[3-oxo-3-[[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]propyl]-4-(trifluoromethoxy)-
  • ER-HoxA9,Dihydroorotate Dehydrogenase,inhibit,AML,ML 390,differentiatio,U937,DHODH,ML390,myeloid,ML-390,Inhibitor,THP1
  • (R)-N-(3-Oxo-3-((1,2,3,4-tetrahydronaphthalen-1-yl)amino)propyl)-4-(trifluoromethoxy)benzamide
  • ML390, 10 mM in DMSO
CAS:
2029049-79-2
MF:
C21H21F3N2O3
MW:
406.4
Mol File:
2029049-79-2.mol
More
Less

ml390 Chemical Properties

Boiling point:
599.7±50.0 °C(Predicted)
Density 
1.31±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
≥40.6 mg/mL in DMSO; insoluble in H2O; ≥17.47 mg/mL in EtOH
form 
solid
pka
13.65±0.46(Predicted)
color 
White to off-white
More
Less

ml390 Usage And Synthesis

Description

ML-390 is an inhibitor of dihydroorotate dehydrogenase (DHODH), the enzyme that converts dihydroorotate to orotate during de novo pyrimidine synthesis. In acute myeloid leukemia, leukemic myeloblast development is halted at an immature stage leading to perpetual self-renewal rather than differentiation. ML-390 induces differentiation in the acute myeloid leukemia cell lines U937 (murine) and THP-1 (human) cell lines with an EC50 value of approximately 2 μM.

Uses

ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models[1][2][3].

in vitro

in the screening study, ml390 was identified as the most potent compound against the engineered erhox-gfp cell line. moreover, the addition of uridine to the cell culture media could abrogate the differentiation effects of ml390, demonstrating further evidences that ml390’ effects were due to their inhibition of dhodh-catalyzed pyrimidine synthesis. in addition, ml390 was found to be not able to inhibit dhodh in the p. falciparum parasite, which is the causative agent of malaria. furthermore, the x-ray structure indicated that the binding of ml390 to the enzyme might be increased by modifying ml390 with a ring in its central portion to lock the molecule into its binding conformation with the amide substituents [1].

IC 50

0.56 μm

References

[1] timothy a lewis et al. development of ml390: a human dhodh inhibitor that induces differentiation in acute myeloid leukemia. acs med chem lett 2016 dec 28;7(12):1112-1117. epub 2016 sep 28.

ml390Supplier

Shanghai Beckham Medical Technology Co., Ltd
Tel
13816613772
Email
huahero21@sina.com
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
Shanghai Chaolan Chemical Technology Center
Tel
021-QQ:65489617 15618227136
Email
Sales@ATKchemical.com
Beijing Solarbio Science & Tecnology Co., Ltd.
Tel
010-50973130 18101056239
Email
3193328036@qq.com
Twochem Co.Ltd.
Tel
021-58111628 15800915896
Email
sales@twochem.com